Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare vasculitis: experimental drug enters Mid-Stage trial

NCT ID NCT07160608

Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called tarperprumig in 75 adults with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal is to see if the drug is safe and can help control the disease by reducing inflammation. Participants will receive either the drug or a placebo, and doctors will monitor for side effects and signs of remission.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed or relapsing ANCA-associated vasculitis, GPA and MPA subtypes consistent with the 2022 ACR/EULAR classification criteria for GPA and MPA for whom treatment with rituximab or cyclophosphamide is considered. * Positive test for antibodies to either PR3-ANCA or MPO-ANCA at Screening or in the past by a quantitative assay (for example, ELISA, bead assay). * At least one major item, or at least 3 minor items, or at least 2 renal items in the BVAS. Exclusion Criteria: * Other systemic diseases that, in the judgment of the Investigator, constitute the primary illness, including but not limited to: eosinophilic granulomatosis with polyangiitis (EGPA), systemic lupus erythematosus, IgA nephropathy and/or IgA associated vasculitis with or without Henoch-Schonlein purpura, rheumatoid vasculitis, Sjogren's syndrome, anti-GBM disease, cryoglobulinemic vasculitis, autoimmune hemolytic anemia, or mixed connective tissue disease. * Alveolar hemorrhage requiring invasive pulmonary ventilation support at Screening. * Any diseases or conditions that, in the judgment of the Investigator, present a substantial clinical risk to participate in this study. * For patients with a previous diagnosis of CKD, patients known to have a stable eGFR for greater than 3 months prior to Screening and a decline less than 25% of previous eGFR at Screening will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA associated vasculitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis granulomatosis with polyangiitis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anti-neutrophil cytoplasmic antibody-associated vasculitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    76 sites in 14 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Ciudad de Buenos Aires, C1015ABO, Argentina

  • Research Site

    RECRUITING

    Ciudad de Buenos Aires, C1181ACH, Argentina

  • Research Site

    RECRUITING

    La Plata, B1900AXI, Argentina

  • Research Site

    RECRUITING

    Rosario, S2000DEJ, Argentina

  • Research Site

    RECRUITING

    San Juan Bautista, 1888, Argentina

  • Research Site

    WITHDRAWN

    Santa Fe, S3000, Argentina

  • Research Site

    RECRUITING

    Clayton, 3168, Australia

  • Research Site

    RECRUITING

    Heidelberg, 3084, Australia

  • Research Site

    RECRUITING

    Nedlands, 6009, Australia

  • Research Site

    RECRUITING

    Wollongong, 2500, Australia

  • Research Site

    RECRUITING

    Barretos, 14784-057, Brazil

  • Research Site

    RECRUITING

    Belo Horizonte, 30130-100, Brazil

  • Research Site

    RECRUITING

    Porto Alegre, 90035-903, Brazil

  • Research Site

    RECRUITING

    Recife, 50670-420, Brazil

  • Research Site

    RECRUITING

    São Paulo, 01323-001, Brazil

  • Research Site

    RECRUITING

    São Paulo, 04038-002, Brazil

  • Research Site

    RECRUITING

    São Paulo, 05430-010, Brazil

  • Research Site

    RECRUITING

    Calgary, Alberta, T2N 1N4, Canada

  • Research Site

    RECRUITING

    Edmonton, Alberta, T6G 2X8, Canada

  • Research Site

    RECRUITING

    Etobicoke, Ontario, M9W 6V1, Canada

  • Research Site

    RECRUITING

    Hamilton, Ontario, L8N 4A6, Canada

  • Research Site

    RECRUITING

    Toronto, Ontario, M5T 3L9, Canada

  • Research Site

    RECRUITING

    Montreal, Quebec, H4J 1C5, Canada

  • Research Site

    RECRUITING

    Baotou, 014010, China

  • Research Site

    RECRUITING

    Beijing, 100034, China

  • Research Site

    RECRUITING

    Beijing, 100730, China

  • Research Site

    RECRUITING

    Guangzhou, 510080, China

  • Research Site

    RECRUITING

    Hangzhou, 310003, China

  • Research Site

    RECRUITING

    Nanchang, 330006, China

  • Research Site

    RECRUITING

    Shenzhen, 518036, China

  • Research Site

    RECRUITING

    Marseille, 13385, France

  • Research Site

    RECRUITING

    Paris, 75014, France

  • Research Site

    RECRUITING

    Paris, 75015, France

  • Research Site

    RECRUITING

    Strasbourg, 67091, France

  • Research Site

    RECRUITING

    Toulouse, 31059, France

  • Research Site

    RECRUITING

    Berlin, 10117, Germany

  • Research Site

    RECRUITING

    Essen, 45147, Germany

  • Research Site

    RECRUITING

    Göttingen, 37075, Germany

  • Research Site

    RECRUITING

    Ludwigshafen, 67063, Germany

  • Research Site

    RECRUITING

    München, 81377, Germany

  • Research Site

    RECRUITING

    Brescia, 25123, Italy

  • Research Site

    RECRUITING

    Padova, 35128, Italy

  • Research Site

    RECRUITING

    Pavia, 27100, Italy

  • Research Site

    RECRUITING

    Pisa, 56126, Italy

  • Research Site

    RECRUITING

    Gdansk, 80-214, Poland

  • Research Site

    RECRUITING

    Krakow, 30-688, Poland

  • Research Site

    RECRUITING

    Poznan, 60-355, Poland

  • Research Site

    RECRUITING

    Warsaw, 04-141, Poland

  • Research Site

    WITHDRAWN

    Daegu, 41944, South Korea

  • Research Site

    RECRUITING

    Daegu, 42472, South Korea

  • Research Site

    RECRUITING

    Daejeon, 35015, South Korea

  • Research Site

    RECRUITING

    Seoul, 03080, South Korea

  • Research Site

    RECRUITING

    Seoul, 03722, South Korea

  • Research Site

    RECRUITING

    Seoul, 04763, South Korea

  • Research Site

    RECRUITING

    Seoul, 08308, South Korea

  • Research Site

    RECRUITING

    Seoul, 135-710, South Korea

  • Research Site

    RECRUITING

    Wŏnju, 26426, South Korea

  • Research Site

    RECRUITING

    Barcelona, 08036, Spain

  • Research Site

    RECRUITING

    Pamplona, 31008, Spain

  • Research Site

    RECRUITING

    San Sebastián de los Reyes, 28702, Spain

  • Research Site

    RECRUITING

    Santander, 39008, Spain

  • Research Site

    RECRUITING

    Seville, 41013, Spain

  • Research Site

    RECRUITING

    Kaohsiung City, 81362, Taiwan

  • Research Site

    RECRUITING

    Taichung, 40705, Taiwan

  • Research Site

    RECRUITING

    Taipei, 114, Taiwan

  • Research Site

    RECRUITING

    Taoyuan, 333, Taiwan

  • Research Site

    RECRUITING

    Altındağ, 06230, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Ankara, 5000, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Center, 23200, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Istanbul, 34098, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Istanbul, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Kocaeli, 41380, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Birmingham, B15 2GW, United Kingdom

  • Research Site

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

  • Research Site

    RECRUITING

    Leicester, LE5 4PW, United Kingdom

  • Research Site

    RECRUITING

    London, NW3 2QG, United Kingdom

  • Research Site

    RECRUITING

    London, W12 0HS, United Kingdom

  • Research Site

    RECRUITING

    Manchester, M13 9WL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.